ID   KKP HR
AC   CVCL_WH06
DR   Wikidata; Q94340160
RX   PubMed=26919099;
CC   Doubling time: 27 hours (PubMed=26919099).
CC   Selected for resistance to: DrugBank; DB00072; Trastuzumab (Herceptin).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Ser903Arg (c.2709T>G); Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3430; ERBB2; Simple; p.Pro1170Ala (c.3508C>G); ClinVar=VCV000134082; Zygosity=Unspecified (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 3431; ERBB3; Simple; p.Thr757Lys (c.2270C>A); Zygosity=Unspecified (from parent cell line).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C4004; Gastric adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_WH05 ! KKP
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 24-05-19; Last updated: 29-06-23; Version: 7
//
RX   PubMed=26919099; DOI=10.18632/oncotarget.7575; PMCID=PMC4951299;
RA   Arienti C., Zanoni M., Pignatta S., Del Rio A., Carloni S.,
RA   Tebaldi M., Tedaldi G., Tesei A.;
RT   "Preclinical evidence of multiple mechanisms underlying trastuzumab
RT   resistance in gastric cancer.";
RL   Oncotarget 7:18424-18439(2016).
//